BURLINGAME, CA AND BASILEA, SUIZA / ACCESSWIRE / September 15, 2020 / Humanigen, a clinically organized biopharmaceutical company aimed at the prevention and remedy of an immune hyperresposed called cytokine storm, and Lonza today announced a strategic collaboration to expand the production capacity of lenzilumab, recently in phase 3 clinical trials for COVID-19, prior to the prospective approval of emergency use in 2020 and the forthcoming commercialization.
This Humanigen collaboration to leverage the manufacture of monoclonal antibodies and Lonza. Lenzilumab’s regulatory expertise represents Humanigen’s exclusive Humaneered® Human-colony stimulating monoclonal antibody (GM-CSF), capable of preventing and treating cytokine storm, which is believed to cause respiratory misery syndrome in severe cases of COVID-19.
More main points on Humanigen systems can be discovered at COVID-19 in www. humanigen. com/covid-19, and the main points of the prospective Phase 3 registration exam in the United States can be discovered in Clinicaltrials. gov ClinicalTrials. gov NCT04351152 Identifier.
We are a beloved global spouse in the pharmaceutical, biotechnology and special ingredients markets. We work to prevent you from disease and promote a healthier world by enabling our customers to deliver cutting-edge drugs that help treat or even cure a wide variety of diseases. To offer a wide variety of microbial solutions, which help create and maintain a healthy environment.
Founded in 1897 in the Swiss Alps, Lonza now operates in 120 locations and offices in more than 35 countries. With approximately 15,500 full-time workers, we are made up of high-performance groups and individual workers who make a significant difference in ours. , as well as the communities in which we operate. The company generated revenues of 5. 9 billion francs in 2019 with A CORE EBITDA of 1. 6 billion francs. For more information, www. lonza. com and stay with us on Twitter @LonzaGroup Facebook @LonzaGroupAG.
The company is also focusing on creating next-generation car-T mixing remedies published through genes that employ methods to enhance while employing GM-CSF genetic suppression technologies to control toxicity. EphA3-CAR-T portfolio for various counterfeit cancers and EMR1-CAR-T for various eosinophil disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either by using lenzilumab as a neutralizing antibody or by removing GM -CSF gene) in mixture with other T-CAR-T, bispecific or herbicide (NK) T mobiles. Initiate immunotherapy remedies to cut the link in efficacy/toxicity, adding to save it and/or treat graft-versus-host disease (GvHD) in patients undergoing a mobile allogeneic hematopoietic stem transplant (GCSH). In addition, Humanigen and Kite, a Gilead company, compare lenzilumab in mixture with Yescarta® (ciloleucel axicabtagen) in patients with relucking or refractory giant B mobile lymphoma in clinical collaboration. For more information, visit www. humanigen. com.
All forward-looking statements are expressly qualified in their entirety through this warning. You deserve not to place undue reliance on forward-going statements, which relate only to the date of this release. We assume no legal responsibility to review or update any -Statements made in this press release to reflect occasions or cases after the date of this fact or to reflect new data or the occurrence of unforeseen occasions, as required by law.
Certain problems addressed in this press release may constitute forward-going statements. These statements are based on the existing expectations and estimates of Lonza Group Ltd. , Lonza Group Ltd cannot provide any assurance that those expectations and estimates will be met. All forward-looking statements involve dangers and uncertainties and are fully qualified. The actual effects may differ materially in the long term from the forward-looking statements contained in this press release due to a variety of factors. In the form required by law, Lonza Group Ltd disclaims any legal objective or liability to update the statements contained in this press release.
SOURCE: Humanigen, Inc.